Collegium Pharmaceutical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vikram Karnani
- Full Time Employees
- 357
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 100 Technology Center Drive Stoughton MA United States of America 02072
- IPO Date
- May 7, 2015
- CIK
- 0001267565
- Website
- collegiumpharma.com
- Similar Companies
- Business
- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is a diversified biopharmaceutical company focused on developing, licensing, and commercializing differentiated medications for serious medical conditions, including moderate to severe pain and attention deficit hyperactivity disorder (ADHD); its commercial portfolio features Jornay PM, a central nervous system stimulant for ADHD treatment taken in the evening; Belbuca, a buprenorphine-containing buccal film for persistent pain requiring around-the-clock opioid analgesia; Xtampza ER, an abuse-deterrent extended-release oral oxycodone formulation; Nucynta ER and Nucynta IR, extended-release and immediate-release tapentadol products for severe pain management; and Symproic, an opioid antagonist available in the United States. Founded in 2002 and headquartered in Stoughton, Massachusetts, the company operates primarily in the U.S. market, leveraging its DETERx platform technology for abuse-deterrent formulations and pursuing growth in pain management and neuropsychiatry segments through strategic portfolio expansion. In late 2024, Collegium completed the US$525 million acquisition of Ironshore Pharmaceuticals, integrating Jornay PM to establish a foothold in ADHD treatment and diversify beyond opioids; it also launched a US$150 million share repurchase program in early 2024, executing a US$25 million accelerated share repurchase in May 2025 while reporting 23% year-over-year revenue growth in the first quarter of 2025 driven by pain products and Jornay PM.
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference
Collegium to Participate in Upcoming Investor Conferences
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD
Head to Head Contrast: Collegium Pharmaceutical (NASDAQ:COLL) versus electroCore (NASDAQ:ECOR)
Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference